Merck
  • Home
  • Search Results
  • Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.

Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.

British journal of clinical pharmacology (2014-06-10)
Ana B Santoro, Daniela D Vargens, Mateus de Camargo Barros Filho, Daniel A Bulzico, Luiz Paulo Kowalski, Ricardo M R Meirelles, Daniela P Paula, Ronaldo R S Neves, Cencita N Pessoa, Claudio J Struchine, Guilherme Suarez-Kurtz
ABSTRACT

To evaluate the impact of genetic polymorphisms in uridine 5'-glucuronosylytansferases UGT1A1 and UGT1A3 and iodothyronine-deiodinases types 1 and 2 on levothyroxine (T4 ; 3,5,3',5'-triiodo-L-thyronine) dose requirement for suppression of thyrotropin (TSH) secretion in patients with differentiated thyroid cancer (DTC). Patients (n = 268) submitted to total thyroidectomy and ablation by (131) I, under T4 therapy for at least 6 months were recruited in three public institutions in Brazil. Multivariate regression modelling was applied to assess the association of T4 dosing with polymorphisms in UGT1A1 (rs8175347), UGT1A3 (rs3806596 and rs1983023), DIO1 (rs11206244 and rs2235544) and DIO2 (rs225014 and rs12885300), demographic and clinical variables. A regression model including UGT1A haplotypes, age, gender, body weight and serum TSH concentration accounted for 39% of the inter-individual variation in the T4 dosage. The association of T4 dose with UGT1A haplotype is attributed to reduced UGT1A1 expression and T4 glucuronidation in liver of carriers of low expression UGT1A1 rs8175347 alleles. The DIO1 and DIO2 genotypes had no influence of T4 dosage. UGT1A haplotypes associate with T4 dosage in DTC patients, but the effect accounts for only 2% of the total variability and recommendation of pre-emptive UGT1A genotyping is not warranted.

MATERIALS
Product Number
Brand
Product Description

USP
Calcium Carbonate (AS), United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Calcium carbonate, BioReagent, suitable for insect cell culture, ≥99.0%
Sigma-Aldrich
Calcium carbonate, BioXtra, ≥99.0%
Supelco
Calcium carbonate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Calcium carbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E170, precipitated, 98.5-100.5% (based on anhydrous substance)
Sigma-Aldrich
Calcium carbonate, Vetec, reagent grade, 99%
Sigma-Aldrich
Calcium carbonate, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Sigma-Aldrich
Calcium carbonate, ReagentPlus®
Sigma-Aldrich
Calcium carbonate, ACS reagent, ≥99.0%, powder
Sigma-Aldrich
Calcium carbonate, ACS reagent, chelometric standard, 99.95-100.05% dry basis
Sigma-Aldrich
Calcium carbonate, powder, ≤50 μm particle size, 98%
Sigma-Aldrich
Calcium carbonate, ≥99.995% trace metals basis
Sigma-Aldrich
Calcium carbonate, tested according to Ph. Eur.
Sigma-Aldrich
Calcium carbonate, BioUltra, precipitated, ≥99.0% (KT)
Supelco
Calcium carbonate, certified reference material for titrimetry, certified by BAM, ≥99.5%
Sigma-Aldrich
Calcium carbonate, 99.999% trace metals basis